Benzinga | Aug 5, 2021 04:41PM EDT

Caladrius Biosciences Q2 EPS $(0.10) Beats $(0.14) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 68.75 percent increase over losses of $(0.32) per share from the same period last year.